Agenus Inc.
AGEN Real Time Price USDRecent trades of AGEN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AGEN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Apr 16, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Jan 22, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$30,000 Oct 16, 2023 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$10,000 Jul 20, 2018 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Jan 18, 2018 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
AGEN Revenue by Segment or Geography
New patents grants
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Mar. 11, 2025
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof Jan. 07, 2025
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof Jun. 18, 2024
-
Patent Title: Antibodies and methods of use thereof May. 28, 2024
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof May. 28, 2024
-
Patent Title: Anti-gitr antibodies and methods of use thereof Feb. 13, 2024
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof Dec. 12, 2023
-
Patent Title: Anti-tigit and anti-cd96 antibodies Aug. 08, 2023
-
Patent Title: Anti-cd73 antibodies and methods of use thereof Jul. 04, 2023
-
Patent Title: Antibodies that specifically bind human cd96 Jun. 20, 2023
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 02, 2023
-
Patent Title: Methods of administering anti-ox40 antibodies Oct. 18, 2022
-
Patent Title: Antibodies and methods of use thereof Sep. 20, 2022
-
Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies Aug. 16, 2022
-
Patent Title: Anti-gitr antibodies and methods of use thereof Aug. 02, 2022
-
Patent Title: Anti-ox40 antibodies and anti-gitr antibodies Jun. 14, 2022
-
Patent Title: Anti-pd-1 antibodies and methods of use thereof May. 31, 2022
-
Patent Title: Vectors comprising nucleic acids encoding anti-ox40 antibodies May. 17, 2022
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Mar. 08, 2022
-
Patent Title: Anti-cd137 antibodies and methods of use thereof Feb. 08, 2022
-
Patent Title: Anti-ox40 antibodies Oct. 05, 2021
-
Patent Title: Anti-cd137 antibodies and methods of use thereof Aug. 24, 2021
-
Patent Title: Heat shock protein-binding peptide compositions and methods of use thereof Jul. 20, 2021
-
Patent Title: Anti-tigit antibodies and methods of use thereof Jun. 01, 2021
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 25, 2021
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Feb. 09, 2021
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof Feb. 09, 2021
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof Jan. 05, 2021
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof Nov. 24, 2020
-
Patent Title: Antibodies and methods of use thereof Nov. 17, 2020
-
Patent Title: Anti-gitr antibodies and methods of use thereof Nov. 10, 2020
-
Patent Title: Anti-gitr antibodies and methods of use thereof Oct. 13, 2020
-
Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies May. 05, 2020
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof May. 05, 2020
-
Patent Title: Anti-gitr antibodies and methods of use thereof Mar. 03, 2020
-
Patent Title: Vaccines for treatment and prevention of cancer Feb. 25, 2020
-
Patent Title: Identification of antigen- or ligand-specific binding proteins Dec. 10, 2019
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Nov. 19, 2019
-
Patent Title: Anti-pd-1 antibodies and methods of use thereof Oct. 22, 2019
-
Patent Title: Anti-pd-1 antibodies and methods of use thereof Jun. 18, 2019
-
Patent Title: Anti-gitr antibodies and methods of use thereof May. 07, 2019
-
Patent Title: Anti-ox40 antibodies Apr. 16, 2019
-
Patent Title: Anti-gitr antibodies and methods of use thereof Dec. 18, 2018
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Dec. 04, 2018
-
Patent Title: Cell surface display, screening and production of proteins of interest May. 09, 2017
-
Patent Title: Identification of antigen or ligand-specific binding proteins Mar. 14, 2017
-
Patent Title: Vaccine for treatment and prevention of herpes simplex virus infection Sep. 24, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to AGEN
Recent picks made for AGEN stock on CNBC
ETFs with the largest estimated holdings in AGEN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AGEN stock a Buy, Sell, or Hold?
- What is the price target for $AGEN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AGEN stock?
- Who owns the most shares of $AGEN stock?
- What funds own $AGEN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.